The deal comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital Markets ...

First patient dosed in a Phase 1b/2 study evaluating STC-15, a METTL3 inhibitor, in combination with LOQTORZI, a next-generation PD-1 inhibitor –REDWOOD CITY, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- ...

These findings are consistent with the mechanism of action of spartalizumab and with data reported for inhibitors of PD-1 in other indications. 11 In summary, spartalizumab demonstrated promising ...

Novel Mechanism: APVO711 is a bispecific antibody targeting PD-L1 × CD40-combining checkpoint inhibition with immune ... tumor responses achieved with PD-1/PD-L1 blockade alone.

In trials, the drug has been effective in some tumors, but researchers at the University of Turku in Finland hope to identify biomarkers to better select patients.

Leronlimab increased PD-L1 in patients with triple-negative breast cancer, potentially making cold tumors responsive to ...

From antibody-drug conjugates to PARP inhibitors, innovative treatments are offering new hope for patients with ...

The FDA also approved the use of Zynyz as a monotherapy for patients with squamous cell carcinoma of the anal canal who are ...